Zenas BioPharma (ZBIO) Return on Capital Employed (2024 - 2026)

Zenas BioPharma's Return on Capital Employed history runs 3 years deep, the most recent figure standing at 83.86% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 2650.0% year-over-year to 83.86% in Q1 2026; TTM through Mar 2026 was 83.86%, a 2650.0% decrease from a year earlier, with the FY2025 full-year figure at 121.93%, down 2063.0% from the prior year.
• Return on Capital Employed advanced to 83.86% in Q1 2026 per ZBIO's latest filing, from 132.01% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 49.75% in Q4 2024 and bottomed at 132.01% in Q4 2025.
• The 3-year median for Return on Capital Employed is 75.67% (2025), against an average of 79.05%.
• Across the five-year window, Return on Capital Employed sank 8225 bps in 2025 and plunged 2650 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 49.75% in 2024, then plunged by 165 bps to 132.01% in 2025, then jumped by 36 bps to 83.86% in 2026.
• Per Business Quant, the three latest ZBIO Return on Capital Employed figures stand at 83.86% (Q1 2026), 132.01% (Q4 2025), and 78.66% (Q3 2025).